PE20040552A1 - Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo - Google Patents

Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo

Info

Publication number
PE20040552A1
PE20040552A1 PE2003001035A PE2003001035A PE20040552A1 PE 20040552 A1 PE20040552 A1 PE 20040552A1 PE 2003001035 A PE2003001035 A PE 2003001035A PE 2003001035 A PE2003001035 A PE 2003001035A PE 20040552 A1 PE20040552 A1 PE 20040552A1
Authority
PE
Peru
Prior art keywords
protein
critical
cellular
concentration
viability
Prior art date
Application number
PE2003001035A
Other languages
English (en)
Inventor
Rodriguez Rolando Perez
Vitlloch Adolfo Jose Castillo
Sarazola Svieta Victores
Ayo Tammy Boggiano
Del Calvo Luis Ernesto Rojas
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of PE20040552A1 publication Critical patent/PE20040552A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • C12N5/0694Cells of blood, e.g. leukemia cells, myeloma cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95Protein-free medium and culture conditions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production

Abstract

SE REFIERE A UN METODO EN EL CUAL UNA LINEA CELULAR DE MAMIFERO COMO UN MIELOMA, PARTICULARMENTE NSO QUE CONTIENE UNA SECUENCIA QUE CODIFICA UNA PROTEINA O POLIPEPTIDO RECOMBINANTE; ES ADAPTADA A CRECER EN UN MEDIO LIBRE DE SUERO Y PROTEINA, EL PROCEDIMIENTO COMPRENDE DOS ETAPAS: I) UNA ETAPA NO CRITICA EN LA CUAL A PARTIR DE UNA LINEA CON UNA VIABILIDAD CELULAR ENTRE 80% Y 100% LAS CELULAS CRECEN SUCESIVAMENTE EN MEDIO DE CULTIVO CON CONCENTRACIONES DECRECIENTES DE PROTEINA HASTA ALCANZARSE UNA CONCENTRACION CRITICA DE PROTEINA DONDE LA VIABILIDAD CAE A 0%; II) UNA ETAPA CRITICA EN EL CUAL UNA VEZ DETERMINADA LA CONCENTRACION CRITICA (ESTAS CONCENTRACIONES SON ESPECIFICAS PARA CADA LINEA CELULAR Y GENERALMENTE ESTAN POR DEBAJO DE 0,6 MG/ML) SE BUSCA LA CONCENTRACION ANTERIOR DONDE AUN EXISTE CRECIMIENTO CELULAR CONSIDERADA COMO CONCENTRACION PRE-CRITICA Y A PARTIR DE LA MISMA SE DISMINUYE LENTAMENTE DICHA CONCENTRACION DE PROTEINA HASTA QUE LAS CELULAS RECUPEREN SU VIABILIDAD Y EL TIEMPO DE DOBLAJE ORIGINAL. TAMBIEN SE INDICA QUE LAS LINEAS CELULARES QUE CRECEN ESTABLEMENTE EN ESTAS CONDICIONES DE MEDIO LIBRE DE SUERO Y PROTEINAS ES POR AL MENOS 40 GENERACIONES, ADICIONALMENTE LOS CLONES OBTENIDOS EXPRESAN LOS ANTICUERPOS ANTI RECEPTOR DE EGF hR3, EL ANTI CD6 T1hT HUMANIZADOS Y EL ANTICUERPO QUIMERICO ANTI CD3 T3Q ADEMAS DE LOS FRAGMENTOS DE DICHOS ANTICUERPOS
PE2003001035A 2002-10-23 2003-10-10 Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo PE20040552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20020239A CU23097A1 (es) 2002-10-23 2002-10-23 Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método

Publications (1)

Publication Number Publication Date
PE20040552A1 true PE20040552A1 (es) 2004-10-26

Family

ID=40134843

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001035A PE20040552A1 (es) 2002-10-23 2003-10-10 Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo

Country Status (27)

Country Link
US (2) US20060036082A1 (es)
EP (2) EP2363418B1 (es)
JP (1) JP4674087B2 (es)
KR (1) KR101186048B1 (es)
CN (1) CN1714147B (es)
AR (1) AR041645A1 (es)
AT (1) ATE502103T1 (es)
AU (1) AU2003273727B2 (es)
CA (1) CA2503315C (es)
CU (1) CU23097A1 (es)
DE (1) DE60336415D1 (es)
DK (1) DK1564285T3 (es)
EA (1) EA007465B1 (es)
EC (1) ECSP055740A (es)
ES (2) ES2624279T3 (es)
GE (1) GEP20084444B (es)
HK (1) HK1084414A1 (es)
HR (1) HRP20050760A2 (es)
LT (1) LT5354B (es)
LV (1) LV13361B (es)
MY (1) MY144088A (es)
NZ (1) NZ540171A (es)
PE (1) PE20040552A1 (es)
PT (1) PT1564285E (es)
TN (1) TNSN05116A1 (es)
UY (1) UY28037A1 (es)
WO (1) WO2004038010A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104673754B (zh) * 2015-02-14 2018-03-02 百泰生物药业有限公司 重组骨髓瘤细胞克隆的筛选方法及由此获得的抗体分子
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3694263A (en) * 1970-10-23 1972-09-26 Joseph J Korn Sr Swimming pool cleaning methods and apparatus therefor
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US3886616A (en) * 1972-12-06 1975-06-03 Fay A Hayes Hand propelled swimming pool cleaner
US4275474A (en) * 1979-04-30 1981-06-30 Woodard Randle C Vacuum head for swimming pool cleaning system
US4240174A (en) * 1979-07-30 1980-12-23 Scott Jeffrey L Self-contained mobile pool cleaning apparatus
US4430214A (en) * 1982-09-15 1984-02-07 Baker Marvin E Strainer mill for swimming pool pump intake
AU2986484A (en) * 1983-06-27 1985-01-03 Monash University Leptospira strains grown in protein free medium
US4558479A (en) * 1984-01-26 1985-12-17 Alopex Industries, Inc. Pool cleaner
US4683599A (en) * 1984-03-30 1987-08-04 Fahet Nv Automatic pool cleaner fitting
US4581075A (en) * 1985-03-15 1986-04-08 Maxi-Sweep, Inc. Self-propelled water borne pool cleaner
AU6291090A (en) 1989-09-29 1991-04-28 Atomic Energy Of Canada Limited Infrared-based gas detector
JP2696001B2 (ja) 1991-04-15 1998-01-14 財団法人化学及血清療法研究所 組換え蛋白質産生用培地
EP0531562A1 (de) 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
PT784684E (pt) * 1994-09-16 2007-11-23 Cancer Res Fund Of Contra Cost ''péptidos recontinantes derivados do anticorpo mc3 anti-ba46, métodos para a sua utilização e métodos de hmnanização de péptidos do anticorpo''
JP3158157B2 (ja) 1994-11-10 2001-04-23 バクスター・アクチエンゲゼルシャフト 無蛋白培養における生物製剤の製造法
AU703484B2 (en) 1995-02-23 1999-03-25 Quest International Services B.V. Peptides for tissue and cell culture media
AUPN442295A0 (en) 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Also Published As

Publication number Publication date
WO2004038010A1 (es) 2004-05-06
CA2503315A1 (en) 2004-05-06
GEP20084444B (en) 2008-08-10
HRP20050760A2 (en) 2006-08-31
UY28037A1 (es) 2004-04-30
ECSP055740A (es) 2005-09-20
MY144088A (en) 2011-08-15
PT1564285E (pt) 2011-04-20
EP1564285B1 (en) 2011-03-16
KR20050088403A (ko) 2005-09-06
LT2005053A (en) 2006-04-25
JP4674087B2 (ja) 2011-04-20
DK1564285T3 (da) 2011-05-16
DE60336415D1 (de) 2011-04-28
ATE502103T1 (de) 2011-04-15
EP2363418A2 (en) 2011-09-07
EP2363418B1 (en) 2017-02-08
LV13361B (en) 2006-02-20
US20100197011A1 (en) 2010-08-05
KR101186048B1 (ko) 2012-09-25
CA2503315C (en) 2014-02-18
EA200500695A1 (ru) 2005-10-27
LT5354B (lt) 2006-07-25
BR0315565A (pt) 2005-08-23
EA007465B1 (ru) 2006-10-27
CN1714147A (zh) 2005-12-28
EP2363418A3 (en) 2011-11-16
BR0315565B1 (pt) 2022-01-25
US20060036082A1 (en) 2006-02-16
HK1084414A1 (en) 2006-07-28
TNSN05116A1 (en) 2007-05-14
CN1714147B (zh) 2011-01-12
AU2003273727A1 (en) 2004-05-13
EP1564285A1 (en) 2005-08-17
CU23097A1 (es) 2005-11-18
AU2003273727B2 (en) 2008-04-03
ES2360049T3 (es) 2011-05-31
JP2006503879A (ja) 2006-02-02
AR041645A1 (es) 2005-05-26
ES2624279T3 (es) 2017-07-13
NZ540171A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
Rabi et al. A new xinjiangchelyid turtle from the Middle Jurassic of Xinjiang, China and the evolution of the basipterygoid process in Mesozoic turtles
Brochu Phylogenetic relationships of Necrosuchus ionensis Simpson, 1937 and the early history of caimanines
DE69521794D1 (de) Zellen mit mehreren geänderten epitopen auf einem oberflächeantigen zur verwendung in transplantation
Potter Plasma cell neoplasia in a single host: a mosaic of different protein-producing cell types
RU2008126743A (ru) Способ получения фармацевтической композиции
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
Aguilera et al. Palaeontological evidence for the last temporal occurrence of the ancient western Amazonian River outflow into the Caribbean
CN104212763B (zh) 一种***干细胞的分离、培养方法及其用途
de la Fuente et al. Long-necked chelid turtles from the Campanian of northwestern Patagonia with comments on K/P survivorship of the genus Yaminuechelys
Weihing et al. Purification of hepatic microsomal membranes
Muldoon et al. Early Holocene fauna from a new subfossil site: A first assessment from Christmas River, south central Madagascar
Hershkovitz et al. Manot 1 calvaria and recent modern human evolution: An anthropological perspective
PE20040552A1 (es) Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo
Jordan et al. High-risk donors: expanding donor criteria
Bunch et al. Generation of a mouse sperm membrane fraction with zona receptor activity
ATE533788T1 (de) Antikörper gegen cd44vra und methoden zu ihrer verwendung
Hegmann et al. Motility-dependence of the heterogenous staining of culture cells by a monoclonal anti-tropomyosin antibody
Thomas et al. Electrophoretic studies of proteins in Avena in relation to genome homology
EA200501323A1 (ru) Получение эритроцитов с модифицированным уровнем экспрессии антигенов групп крови и их применение в контроле качества реагентов для определения группы крови
Stringer The Neanderthal-H. sapiens interface in Eurasia
CN101010587B (zh) 应用特异性抗体分离小型肝细胞的方法
ATE322540T1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
Martinkaitytė et al. Stem Cell Therapy in Multiple Sclerosis: Current Progress and Future Prospects.
Jewell et al. Isolation of parietal cells from guinea-pig gastric mucosa and the immunological characterization of their antigenic structure.
Reisman Medical savings and medical cost: Healthcare and age in a changing Singapore

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed